Plitidepsin clinical trials
How each study uses plitidepsin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 2
PharmaMar (14) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Institut Bergonié (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses plitidepsin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)CompletedPhase 2Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT06766825Written as Plitidepsin 1.5 mg/day
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedPhase 3PharmaMarNCT04784559Written as Plitidepsin
- Extension Study in a Cohort of Adult Patients With COVID-19 InfectionCompletedPhase 1/2PharmaMarNCT05121740Written as Plitidepsin 1.5 mg / day
- Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)TerminatedPhase 2PharmaMarNCT05705167Written as Plitidepsin
- Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19CompletedPhase 1PharmaMarNCT04382066Written as Plitidepsin 1.5 mg/day
- Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter TrialTerminatedPhase 2Institut BergoniéNCT01876043Written as plitidepsin
- Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedPhase 2PharmaMarNCT03117361Written as plitidepsin
- A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate CancerTerminatedPhase 2PharmaMarNCT00780975Written as Aplidin (plitidepsin)
- Aplidin - Dexamethasone in Relapsed/Refractory MyelomaCompletedPhase 3PharmaMarNCT01102426Written as Plitidepsin
- A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell LymphomaTerminatedPhase 2PharmaMarNCT03070964Written as plitidepsin
- Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedPhase 1PharmaMarNCT02100657Written as Plitidepsin
- Clinical Trial of Aplidin® in Patients With Primary MyelofibrosisCompletedPhase 2PharmaMarNCT01149681Written as APLIDIN (plitidepsin)
- Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory LeukemiaTerminatedPhase 1/2PharmaMarNCT00780143Written as Plitidepsin plus Cytarabine
- Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin LymphomaCompletedPhase 2PharmaMarNCT00884286Written as Aplidin®
- Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or LymphomasCompletedPhase 1PharmaMarNCT00788099Written as Plitidepsin and Sorafenib
- A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaCompletedPhase 2PharmaMarNCT00229203Written as Plitidepsin
Codes
What other systems call plitidepsin · ClinicalTrials.gg INT003897
- MeSH (NLM) C098980plitidepsinOne source NLM
- UNII (FDA) Y76ID234HWPLITIDEPSINConfirmed FDA, NLM
- NCI Thesaurus C1689PlitidepsinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C098980 | plitidepsin | One source NLM |
| UNII (FDA) | Y76ID234HW | PLITIDEPSIN | Confirmed FDA, NLM |
| NCI Thesaurus | C1689 | Plitidepsin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.